CancerDrs

Head and Neck Cancer clinical trials in Montana

9 actively recruiting head and neck cancer trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Saint Vincent Healthcare — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Saint James Community Hospital and Cancer Treatment Center — Butte, Montana
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
Phase 2 Recruiting NIH

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Montana:
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
  • Community Medical Center — Missoula, Montana
Phase 2 Recruiting NIH

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it fi…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06029270
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Logan Health Medical Center — Kalispell, Montana
Phase 1, Phase 2 Recruiting Industry

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…

Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Montana:
  • Intermountain Health Cancer Centers of Montana — Billings, Montana
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Montana:
  • Community Hospital of Anaconda — Anaconda, Montana
  • Billings Clinic Cancer Center — Billings, Montana
  • Bozeman Health Deaconess Hospital — Bozeman, Montana
  • Benefis Sletten Cancer Institute — Great Falls, Montana
  • Great Falls Clinic — Great Falls, Montana
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Montana:
  • Massive Bio SYNERGY-AI site — Billings, Montana

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-08-17